Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019

Q1 FY26 results · Apr–Jun 2025

Jubilant Pharmova reported revenue from operations of ₹1,900.70 crore (up 9.8% from Q1 FY25) and net profit of ₹102.50 crore (down 78.7% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY26	Q1 FY25	YoY	Q4 FY25	QoQ
Revenue from operations	1,900.70	1,731.70	+9.8%	1,928.80	−1.5%
Other income	12.00	14.00	−14.3%	11.90	+0.8%
Total income	1,912.70	1,745.70	+9.6%	1,940.70	−1.4%
Profit before share of associates & JVs and tax	154.50	499.70	−69.1%	206.10	−25.0%
Share of profit/(loss) of associates & JVs	(0.10)	0.00		(0.10)
Net profit for the period	102.50	481.80	−78.7%	151.30	−32.3%
Attributable to shareholders of the company	102.90	482.10	−78.7%	153.60	−33.0%
EPS, basic (₹)	6.49	30.44	−78.7%	9.71	−33.2%
Net margin (%)	5.4	27.8		7.8

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY26	Q1 FY25	YoY	Q4 FY25	QoQ
Revenue from operations	59.50	166.70	−64.3%	217.30	−72.6%
Other income	0.70	19.50	−96.4%	17.90	−96.1%
Total income	60.20	186.20	−67.7%	235.20	−74.4%
Profit before tax	6.50	(11.20)	Turned profit	23.50	−72.3%
Net profit for the period	5.80	(10.20)	Turned profit	13.60	−57.4%
EPS, basic (₹)	0.36	(0.64)	Turned profit	0.86	−58.1%
Net margin (%)	9.7	-6.1		6.3

Consolidated

Filed with BSE: 29 Jul 2025, 18:47 IST
Board meeting: 29 Jul 2025
Period: 01 Apr 2025 to 30 Jun 2025
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 29 Jul 2025, 18:47 IST
Board meeting: 29 Jul 2025
Period: 01 Apr 2025 to 30 Jun 2025
Review status: Unaudited
Source: XBRL filing on BSE